JP2025523369A5 - - Google Patents
Info
- Publication number
- JP2025523369A5 JP2025523369A5 JP2024570461A JP2024570461A JP2025523369A5 JP 2025523369 A5 JP2025523369 A5 JP 2025523369A5 JP 2024570461 A JP2024570461 A JP 2024570461A JP 2024570461 A JP2024570461 A JP 2024570461A JP 2025523369 A5 JP2025523369 A5 JP 2025523369A5
- Authority
- JP
- Japan
- Prior art keywords
- product according
- pharmaceutical product
- index
- domain variant
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263347939P | 2022-06-01 | 2022-06-01 | |
| US63/347,939 | 2022-06-01 | ||
| PCT/US2023/067697 WO2023235754A1 (en) | 2022-06-01 | 2023-05-31 | Combination therapies for treating urothelial carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025523369A JP2025523369A (ja) | 2025-07-23 |
| JP2025523369A5 true JP2025523369A5 (cg-RX-API-DMAC10.html) | 2026-05-07 |
Family
ID=87036781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024570461A Pending JP2025523369A (ja) | 2022-06-01 | 2023-05-31 | 尿路上皮癌腫を治療するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010701A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4532548A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025523369A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250022059A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119497722A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023281712A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3253030A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL316971A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024014744A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023235754A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2874306T3 (es) | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| ME03550B (me) | 2012-12-17 | 2020-07-20 | Trillium Therapeutics Inc | Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| DK3298043T3 (da) | 2015-05-18 | 2021-02-15 | Ab Initio Biotherapeutics Inc | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| DK4186927T3 (da) | 2015-10-21 | 2025-06-10 | Ose Immunotherapeutics | Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft |
| WO2017177333A1 (en) | 2016-04-15 | 2017-10-19 | Trillium Therapeutics Inc. | Macrophage stimulation in cd47 blockade therapy |
| EP3493845A4 (en) | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| CN110300764A (zh) | 2017-02-17 | 2019-10-01 | Ose免疫疗法 | 抗SIRPg抗体的新用途 |
| PT3443010T (pt) | 2017-02-17 | 2024-10-21 | Ose Immunotherapeutics | Novos anticorpos anti-sirpa e suas aplicações terapêuticas |
| CA3057718A1 (en) | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
| JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | 抗sirpアルファ抗体 |
| PT3625259T (pt) | 2017-05-16 | 2024-07-04 | Synthon Biopharmaceuticals Bv | Anticorpos anti-sirpalfa |
| EP3658589B1 (en) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| WO2021108693A1 (en) * | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| JP2023542879A (ja) * | 2020-09-17 | 2023-10-12 | アジェンシス,インコーポレイテッド | 191p4d12タンパク質に結合する抗体薬物複合体(adc)を用いたがんの治療方法 |
-
2023
- 2023-05-31 CA CA3253030A patent/CA3253030A1/en active Pending
- 2023-05-31 JP JP2024570461A patent/JP2025523369A/ja active Pending
- 2023-05-31 EP EP23734867.7A patent/EP4532548A1/en active Pending
- 2023-05-31 WO PCT/US2023/067697 patent/WO2023235754A1/en not_active Ceased
- 2023-05-31 KR KR1020247042025A patent/KR20250022059A/ko active Pending
- 2023-05-31 AU AU2023281712A patent/AU2023281712A1/en active Pending
- 2023-05-31 US US18/326,847 patent/US20240010701A1/en active Pending
- 2023-05-31 CN CN202380052100.6A patent/CN119497722A/zh active Pending
- 2023-05-31 IL IL316971A patent/IL316971A/en unknown
-
2024
- 2024-11-28 MX MX2024014744A patent/MX2024014744A/es unknown